Insulin Lispro Market

Insulin Lispro Market, By Type of Insulin Lispro (Rapid-acting Insulin Lispro, Long-acting Insulin Lispro), By Delivery Method (Insulin Pens, Insulin Syringes, Insulin Pumps), By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Others), By Age Group (Pediatric Patients, Adult Patients, Geriatric Patients), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Brand (Humalog (Eli Lilly and Company), Admelog (Sanofi), Other Brands), And By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Insulin lispro is used to treat type 1 diabetes (condition in which the body does not produce insulin and cannot control the amount of sugar in the blood) in people who need insulin therapy. It is always used with another type of insulin, unless it is being used in an external insulin pump. Insulin lispro injection products are also used to improve glycemic control in adults with type 2 diabetes who do not respond well to oral medications alone. Insulin lispro is an analog insulin that differs from human insulin with a change in the sequence of two amino acids, proline at B-28 and lysine at B-29. This change prevents insulin from forming dimers and hexamers, which have lower activity than monomeric insulin. Insulin lispro is rapidly absorbed following subcutaneous administration, reaching peak levels within 2-4 hours and remains effective for 18-30 hours.

Market Dynamics:

The global insulin market has grown significantly in recent years, primarily due to an increase in the number of people living with diabetes and technological advancements in the field of insulin delivery devices. This growth is further expected to be supported by factors such as increasing government initiatives to improve healthcare and rising patient demand for insulin, as well as favorable medical reimbursement policies in developed countries.

Changing lifestyles, such as an increased adoption of sedentary habits and unhealthy diets, have resulted in an increased number of people developing diabetes globally. According to the International Diabetes Federation, there are approximately 382 million people who have diabetes worldwide, and this number is expected to rise to 592 million by 2035. This is likely to fuel the demand for insulin, thereby driving market growth.

However, the market was negatively impacted due to lower diagnosis rate during Covid-19 pandemic.

Key features of the study:

• This report provides in-depth analysis of the global insulin lispro market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global insulin lispro market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Merck & Co., Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Johnson & Johnson Services, Inc., Biocon Limited, Mylan N.V., Boehringer Ingelheim, International GmbH, Wockhardt Ltd., Lupin Pharmaceuticals, Inc., Bioton S.A., and Ypsomed AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global insulin lispro market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin lispro market

Detailed Segmentation:

• Global Insulin Lispro Market, By Type of Insulin Lispro

Rapid-acting Insulin Lispro

Long-acting Insulin Lispro

• Global Insulin Lispro Market, By Delivery Method

Insulin Pens

Insulin Syringes

Insulin Pumps

• Global Insulin Lispro Market, By Indication

Type 1 Diabetes

Type 2 Diabetes

Gestational Diabetes

Others

• Global Insulin Lispro Market, By Age Group

Pediatric Patients

Adult Patients

Geriatric Patients

• Global Insulin Lispro Market, By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

• Global Insulin Lispro Market, By Brand

Humalog (Eli Lilly and Company)

Admelog (Sanofi)

Other Brands

• Global Insulin Lispro Market, By Geography

North America

Europe

Asia Pacific

South America

Middle East & Africa

• Company Profiles

Eli Lilly and Company

Sanofi

Novo Nordisk A/S

Merck & Co., Inc.

Pfizer Inc.

F. Hoffmann-La Roche Ltd.

AstraZeneca PLC

Johnson & Johnson Services, Inc.

Biocon Limited

Mylan N.V.

Boehringer Ingelheim International GmbH

Wockhardt Ltd.

Lupin Pharmaceuticals, Inc.

Bioton S.A.

Ypsomed AG